newzzz
Back to recent news

News Archive

Past news

DiaSorin Molecular Receives Additional BARDA Funding in Support of Submitting the Simplexa™ COVID-19 Direct and the Simplexa™ COVID-19 & Flu A/B Direct kits for FDA 510(k) Clearance

Cypress, California (USA) – January 13, 2021 – DiaSorin Molecular LLC, a subsidiary of DiaSorin S.p.A. (FTSE MIB:DIA), announced today that it has received additional federal funding from the Biomedical Advanced Research and Development Authority (BARDA),…

DiaSorin Molecular’s Simplexa™ COVID-19 Direct Molecular Test CE Marked for Saliva Specimens

Cypress, Calif. (September 17, 2020) – DiaSorin Molecular LLC announced today that it has attained CE Marking for the addition of saliva specimens for use with the Simplexa COVID-19 Direct assay….

DiaSorin Molecular receives FDA clearance for the Simplexa™ Flu A/B & RSV Direct Gen II Assay. A partner to run with the Simplexa™ COVID-19 Direct assay.

Cypress, Calif. (September 8, 2020) – DiaSorin Molecular LLC announced today that it has received FDA Clearance for its Simplexa™ Flu A/B & RSV Direct Gen II kit….

DiaSorin Molecular CE marks their new Simplexa™ Flu A/B & RSV Direct Gen II Assay to run with the Simplexa™ COVID-19 Direct assay

Cypress, Calif. (July 7, 2020) – DiaSorin Molecular LLC announced today that it has CE marked its Simplexa™ Flu A/B & RSV Direct Gen II kit….

DiaSorin Molecular’s Simplexa™ Congenital CMV Direct Assay Attains CE Mark

Cypress, Calif. (June 15, 2020) – DiaSorin Molecular LLC announced today that it has received CE marking for its Simplexa™ Congenital CMV Direct kit. The new molecular diagnostic test enables direct detection of cytomegalovirus DNA in both saliva swab and urine specimens from babies up to 21 days old….